Gabriel Tinoco

机构：The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University · ORCID：0000-0002-2565-6124

发表论文 326 篇 · 总被引 1628 次 · h-index 18

代表论文

Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes (2025 · Nature Communications · 被引 15)
Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma (2025 · Targeted Oncology · 被引 5)
Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer (2025 · Cancer Research Communications · 被引 4)
A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT). (2025 · Journal of Clinical Oncology · 被引 4)
Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER). (2025 · Journal of Clinical Oncology · 被引 3)
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome–immune cell signatures (2026 · Cancer Immunology Immunotherapy · 被引 2)